Skip Navigation

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (41)
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by PEARCE, N.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by PEARCE, N.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 1993 Oxford University Press

other

What Does the Odds Ratio Estimate in a Case-Control Study?

NEIL PEARCE*,{dagger}

* Department of Medicine, Wellington School of Medicine PO Box 7343, Wellington, New Zealand
{dagger} Formerly at IARC 150 cours Albert-Thomas, 69372 Lyon, France

The use of the term ‘odds ratio’ in reporting the findings of case-control studies is technically correct, but is often misleading. The meaning of the odds ratio estimates obtained in a case-control study differs according to whether controls are selected from person-time at risk (the study base), persons at risk (the base-population at risk at the beginning of follow-up), or survivors (the population at risk at the end of follow-up). These three methods of control selection correspond to estimating the rate ratio, risk ratio, or the odds ratio respectively, by means of calculating the odds ratio in the subjects actually studied. None of these estimation procedures depends on any rare disease assumption. Where the rare disease assumption is relevant is whether the effect which is estimated (e.g. the odds ratio) is approximately equal to some other effect measure of interest (e.g. the risk ratio or rate ratio) in the underlying study base. To avoid confusion on this issue, authors should be encouraged to not only specify the manner in which controls have been selected (e.g. by density sampling) but also the corresponding effect measure which is being estimated (e.g. the rate ratio) by the ‘odds ratio’ which is obtained in a case-control analysis.

Received 1 June 1993


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
Am. J. Respir. Crit. Care Med.Home page
S. Kudoh, H. Kato, Y. Nishiwaki, M. Fukuoka, K. Nakata, Y. Ichinose, M. Tsuboi, S. Yokota, K. Nakagawa, M. Suga, et al.
Interstitial Lung Disease in Japanese Patients with Lung Cancer: A Cohort and Nested Case-Control Study
Am. J. Respir. Crit. Care Med., June 15, 2008; 177(12): 1348 - 1357.
[Abstract] [Full Text] [PDF]


Home page
J. Am. Soc. Nephrol.Home page
S. M. Brunelli, J. D. Lewis, M. Gupta, S. M. Latif, M. G. Weiner, and H. I. Feldman
Risk of Kidney Injury Following Oral Phosphosoda Bowel Preparations
J. Am. Soc. Nephrol., December 1, 2007; 18(12): 3199 - 3205.
[Full Text] [PDF]


Home page
ANN INTERN MEDHome page
J. P. Vandenbroucke, E. v. Elm, D. G. Altman, P. C. Gotzsche, C. D. Mulrow, S. J. Pocock, C. Poole, J. J. Schlesselman, M. Egger, and for the STROBE initiative
Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): Explanation and Elaboration
Ann Intern Med, October 16, 2007; 147(8): W-163 - W-194.
[Abstract] [Full Text] [PDF]


Home page
Am J EpidemiolHome page
K. D. Marciante, J. C. Bis, M. J. Rieder, A. P. Reiner, T. Lumley, S. A. Monks, C. Kooperberg, C. Carlson, S. R. Heckbert, and B. M. Psaty
Renin-Angiotensin System Haplotypes and the Risk of Myocardial Infarction and Stroke in Pharmacologically Treated Hypertensive Patients
Am. J. Epidemiol., July 1, 2007; 166(1): 19 - 27.
[Abstract] [Full Text] [PDF]


Home page
JAMAHome page
B. M. Psaty, N. L. Smith, S. R. Heckbert, H. L. Vos, R. N. Lemaitre, A. P. Reiner, D. S. Siscovick, J. Bis, T. Lumley, W. T. Longstreth Jr, et al.
Diuretic Therapy, the {alpha}-Adducin Gene Variant, and the Risk of Myocardial Infarction or Stroke in Persons With Treated Hypertension
JAMA, April 3, 2002; 287(13): 1680 - 1689.
[Abstract] [Full Text] [PDF]


Home page
ThoraxHome page
L J Walsh, C A Wong, J Oborne, S Cooper, S A Lewis, M Pringle, R Hubbard, and A E Tattersfield
Adverse effects of oral corticosteroids in relation to dose in patients with lung disease
Thorax, April 1, 2001; 56(4): 279 - 284.
[Abstract] [Full Text]


Home page
JAMAHome page
B. M. Psaty, N. L. Smith, R. N. Lemaitre, H. L. Vos, S. R. Heckbert, A. Z. LaCroix, and F. R. Rosendaal
Hormone Replacement Therapy, Prothrombotic Mutations, and the Risk of Incident Nonfatal Myocardial Infarction in Postmenopausal Women
JAMA, February 21, 2001; 285(7): 906 - 913.
[Abstract] [Full Text] [PDF]


Home page
YoungHome page
K. Poikolainen, R. Kanerva, and J. Lonnqvist
Fear of nuclear war -- A risk factor for mental disorder among adolescent girls?
Young, December 1, 2000; 8(3): 37 - 46.
[PDF]



Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.